WC
TEVA icon

Wexford Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Wexford Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-55,000
Closed -$845K – 318
2025
Q1 		$845K Buy
+55,000
New +$982K 0.22% 85
2017
Q1 		– Sell
-13,000
Closed -$471K – 235
2016
Q4 		$471K Buy
+13,000
New +$519K 0.05% 130
2015
Q2 		– Sell
-51,650
Closed -$3.22M – 76
2015
Q1 		$3.22M Buy
+51,650
New +$3M 0.94% 22
2014
Q2 		– Sell
-21,000
Closed -$1.11M – 162
2014
Q1 		$1.11M Buy
+21,000
New +$971K 0.08% 108

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Wexford Capital's TEVA Position: Q2 2025 in Review

Wexford Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 55,000 shares — an estimated $845K sold.

Wexford Capital first reported a position in TEVA in Q1 2014 and held it in 4 quarters. The position peaked at $3.22M in Q1 2015. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Wexford Capital reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Wexford Capital sold 55,000 Teva Pharmaceuticals shares in Q2 2025, an estimated $845K.
  • Wexford Capital first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 4 quarters.
  • Wexford Capital's Teva Pharmaceuticals position peaked at $3.22M in Q1 2015.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.